Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination
Jeffery D. Haines(McGill University), Patrizia Casaccia(The Graduate Center, CUNY), Dilara McCauley(Karyopharm Therapeutics (United States)), Belén de la Hera(Icahn School of Medicine at Mount Sinai), Óscar G. Vidaurre(Icahn School of Medicine at Mount Sinai), Qingxiang Sun(University of Electronic Science and Technology of China), Tanja Kuhlmann(University Hospital Münster), Sharon Shacham(Roche (Switzerland)), Yuh Min Chook(The University of Texas Southwestern Medical Center), Grahame J. Kidd(Cleveland Clinic Lerner College of Medicine), Gregory Moy(Allen Institute for Brain Science), Olivier Herbin(Icahn School of Medicine at Mount Sinai), Stefanie Albrecht(University Hospital Münster), Ho Yee Joyce Fung(Southwestern Medical Center), Konstantina Alexandropoulos(Icahn School of Medicine at Mount Sinai)
Cited by 97
Related Papers
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k
Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis
|Brain|2008|851
Sex-specific transcriptional signatures in human depression
|Nature Medicine|2017|802
Multiple sclerosis progression: time for a new mechanism-driven framework
|The Lancet Neurology|2022|624